Goldman Sachs
JANX icon

Goldman Sachs’s Janux Therapeutics JANX Stock Holding History

Goldman Sachs’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
952,675
+350,662
+58% +$5.08M ﹤0.01% 2936
2026
Q1 		$8.37M Sell
602,013
-471,643
-44% -$6.47M ﹤0.01% 3210
2025
Q4 		$14.8M Buy
1,073,656
+418,548
+64% +$9.84M ﹤0.01% 2674
2025
Q3 		$16M Buy
655,108
+306,618
+88% +$7.47M ﹤0.01% 2478
2025
Q2 		$8.05M Buy
348,490
+62,212
+22% +$1.64M ﹤0.01% 2961
2025
Q1 		$7.73M Sell
286,278
-94,069
-25% -$3.55M ﹤0.01% 2929
2024
Q4 		$20.4M Buy
380,347
+64,612
+20% +$3.42M ﹤0.01% 2117
2024
Q3 		$14.3M Sell
315,735
-28,937
-8% -$1.26M ﹤0.01% 2359
2024
Q2 		$14.4M Sell
344,672
-2,499
-0.7% -$117K ﹤0.01% 2160
2024
Q1 		$13.1M Buy
347,171
+307,223
+769% +$6.69M ﹤0.01% 2233
2023
Q4 		$429K Buy
39,948
+25,404
+175% +$220K ﹤0.01% 4846
2023
Q3 		$147K Sell
14,544
-8,175
-36% -$94.3K ﹤0.01% 5112
2023
Q2 		$270K Buy
+22,719
New +$304K ﹤0.01% 5061
2023
Q1 		– Sell
-14,603
Closed -$192K – 6086
2022
Q4 		$192K Buy
14,603
+556
+4% +$8.14K ﹤0.01% 5321
2022
Q3 		$190K Sell
14,047
-1,817
-11% -$24.3K ﹤0.01% 5507
2022
Q2 		$194K Sell
15,864
-2,070
-12% -$24.5K ﹤0.01% 5654
2022
Q1 		$257K Buy
17,934
+3,186
+22% +$52.1K ﹤0.01% 5745
2021
Q4 		$291K Buy
+14,748
New +$309K ﹤0.01% 5684
2021
Q3 		– Sell
-69,000
Closed -$1.72M – 6365
2021
Q2 		$1.72M Buy
+69,000
New +$1.54M ﹤0.01% 4339

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs's JANX Position: Q2 2026 in Review

Goldman Sachs increased its Janux Therapeutics (JANX) stake by 58% in Q2 2026, buying an estimated $5.08M and bringing the position to 952,675 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Goldman Sachs first reported a position in JANX in Q2 2021 and has held it in 19 quarters since. The position peaked at $20.4M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Goldman Sachs held 952,675 shares of Janux Therapeutics worth $14.6M as of Q2 2026.
  • Goldman Sachs bought 350,662 Janux Therapeutics shares in Q2 2026, an estimated $5.08M.
  • Janux Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2936 holding.
  • Goldman Sachs first reported a position in Janux Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Janux Therapeutics position peaked at $20.4M in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.